Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation

J. G. Bender*, S. F. Williams, S. Myers, D. Nottleman, W. J. Lee, K. L. Unverzagt, D. Walker, L. B. To, D. E. Van Epps

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Twenty patients were treated with chemotherapy to mobilize progenitors into the blood. Peripheral blood stem cells were quantitated in peripheral blood or leukapheresis products using colony assays and flow cytometric measurement of CD34+ cells. In four patients where complete sets of serial samples were obtained, the appearance of CD34+ cells preceded the increase in CFU-GM by 24-48 h. Peak levels of CD34+ cells ranged from 0.6-5% and coincided with the peak increase in CFU-GM. Mobilized CD34+ cells contained subsets expressing CD33, CD13, CD45RA, CD38, HLA-DR, CD61 and CD41. Subsets of CD34+ cells expressing CD33, CD13, or CD45RA represent committed myeloid progenitors. In contrast to bone marrow CD34+ cells, few mobilized CD34+ cells expressed CD71, CD7, CD19 or CD10. Prompt engraftment of granulocytes > 500 X 106/l at a median of 13 days and platelets > 50 X 109/l at a median of 15 days was observed in patients reconstituted with mobilized cells. These data indicate that CD34+ cells mobilized during recovery from chemotherapy are predominantly myeloid in phenotype and contain few actively proliferating cells or cells with lymphoid phenotypes.

Original languageEnglish (US)
Pages (from-to)281-285
Number of pages5
JournalBone Marrow Transplantation
Issue number3
StatePublished - 1992

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation'. Together they form a unique fingerprint.

Cite this